XML 69 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
Quarterly Information (unaudited)
12 Months Ended
May 31, 2014
Quarterly Financial Information Disclosure [Abstract]  
QUARTERLY INFORMATION (unaudited)
QUARTERLY INFORMATION (unaudited)

During the preparation of its fiscal 2014 consolidated financial statements, the Company identified an accounting error related to the January 2014 implementation of our global enterprise resource planning system which resulted in the Company recording lower cost of goods sold during the third quarter of 2014. The Company has evaluated the impact of this error and has concluded that this error was not material to any previously issued financial statements. However, the Company has elected to revise this error in the Annual Report on Form 10-K that will be filed with SEC for the period ending May 31, 2014. Additionally, the Company has reflected the revision for these errors in the quarterly financial information tables presented below.











The following table summarizes the impact of immaterial errors in the Company's consolidated statements of operations, consolidated balance sheets and consolidated statements of cash flows for the period ended February 28, 2014:

(In thousands, except per share data)
As Previously Reported
 
Adjustments
 
As Revised
Quarter Ended February 28, 2014
 
 
 
 
 
Consolidated Statement of Operations
 
 
 
 
 
Cost of sales
$
42,560

 
717

 
43,277

Gross profit
45,635

 
(717
)
 
44,918

Operating income
7,569

 
(717
)
 
6,852

Income before income tax provision
5,584

 
(717
)
 
4,867

Income tax expense
476

 
(300
)
 
176

Net income
5,108

 
(417
)
 
4,691

Income per common share
0.15

 
(0.01
)
 
0.14

Income per diluted share
0.14

 
(0.01
)
 
0.13

As of February 28, 2014
 
 
 
 
 
Consolidated Balance Sheets
 
 
 
 
 
Inventory, net
59,834

 
(717
)
 
59,117

Income tax payable
879

 
(300
)
 
579

Nine Months Ended February 28, 2014
 
 
 
 
 
Consolidated Statement of Cash Flows
 
 
 
 
 
Net income
5,108

 
(417
)
 
4,691

Change in inventories
(4,225
)
 
717

 
(3,508
)
Accounts payable, accrued and other liabilities
2,699

 
(300
)
 
2,399

Net cash provided by operating activities
$
15,174

 
 
$
15,174



Quarterly results of operations during the fiscal years ended 2014 and 2013 are as follows:
 
 
2014
 
First
quarter
 
Second
quarter
 
Third
quarter
 
Fourth
quarter
 
(in thousands, except per share data)
Net sales
$
83,579

 
$
88,616

 
$
88,195

 
$
94,065

Gross profit
42,482

 
44,930

 
44,918

 
47,531

Net income (loss)
(426
)
 
(99
)
 
4,691

 
(1,078
)
Earnings per common share
 
 
 
 
 
 
 
Basic
(0.01
)
 

 
0.14

 
(0.03
)
Diluted
(0.01
)
 

 
0.13

 
(0.03
)
 
 
2013
 
First
quarter
 
Second
quarter
 
Third
quarter
 
Fourth
quarter
 
(in thousands, except per share data)
Net sales
$
83,406

 
$
87,007

 
$
81,571

 
$
90,042

Gross profit
39,459

 
44,088

 
41,201

 
44,241

Net income (loss)
(721
)
 
1,969

 
(992
)
 
(868
)
Earnings per common share
 
 
 
 
 
 
 
Basic
(0.02
)
 
0.06

 
(0.03
)
 
(0.03
)
Diluted
(0.02
)
 
0.06

 
(0.03
)
 
(0.03
)

The data in the schedules above has been intentionally rounded to the nearest thousand and therefore the quarterly amounts may not sum to the full year amounts.
The first quarter results of fiscal 2014 included in “Acquisition, restructuring and other items, net”, $1.2 million in Navilyst related acquisition costs and $0.3 million in Clinical Devices related acquisition costs. The second quarter of fiscal 2014 included $1.6 million in Navilyst related acquisition costs and $0.8 million in litigation related costs. The third quarter of fiscal 2014 included $1.4 million in Navilyst related acquisition costs and $1.0 million in consolidation charges. The fourth quarter of fiscal 2014 included $1.3 million in Navilyst related acquisition costs, $1.1 million in litigation charges and $0.4 million in consolidation charges.
The first quarter results for fiscal 2013 included in “Acquisition, restructuring and other items, net”, $2.2 million in transaction and related costs of the Navilyst acquisition and $337 thousand in costs associated with the decision to close our UK facility. The 2013 second quarter results included $1.7 million for Navilyst transaction costs, $476 thousand for the UK closure costs, $425 thousand in litigation costs and $325 thousand in costs related to the Vortex acquisition, offset by $770 thousand gain on sale of a product line. The 2013 third quarter results included $1.6 million in costs related to the discontinuance of a product line, $1.3 million in Navilyst transaction costs, $920 thousand for the UK closure costs, $901 thousand in litigation costs and $414 thousand in transaction costs of the Vortex and Microsulis acquisitions. The 2013 fourth quarter results included $2.1 million for Navilyst transaction costs, $717 thousand in UK closure costs, and $580 thousand in litigation costs.